STOCK TITAN
  1. Home
  2. News
  3. IVVD

Invivyd Inc - IVVD STOCK NEWS

Welcome to our dedicated news page for Invivyd (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Invivyd's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Invivyd's position in the market.

News
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
Rhea-AI Summary
Invivyd, Inc. (IVVD) receives HCPCS reimbursement codes from CMS for PEMGARDA, a COVID-19 prevention drug for immunocompromised individuals. The Q code (Q0224) covers product reimbursement, while the M code (M0224) defines reimbursement for product administration. This development allows for reimbursement through Medicare/Medicaid, representing around 50% of the target population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
none
-
News
Invivyd Announces CEO Transition
Rhea-AI Summary
Invivyd, Inc. appoints Jeremy Gowler as Interim CEO to lead the company's growth phase focused on monoclonal antibody therapies for COVID-19. The company aims to unlock value creation with novel pipeline candidates and a strong balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
none
-
News
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
Rhea-AI Summary
Invivyd, Inc. announces the commercial availability of PEMGARDA for pre-exposure prophylaxis of COVID-19 in immune-compromised individuals in the U.S. The company expects significant revenue in 2024 and ends the year with at least $55 million in cash. PEMGARDA received emergency use authorization from the FDA and is now available for purchase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.82%
Tags
none
News
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Invivyd, Inc. (IVVD) receives emergency use authorization for PEMGARDA™, a monoclonal antibody for COVID-19 pre-exposure prophylaxis. The company's cash position is strong at $200.6 million. Recent At-the-Market share sales raised $40.5 million. The company is focusing on commercial launch plans for PEMGARDA and developing VYD2311, the next anti-SARS-CoV-2 candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11%
Tags
earnings
-
News
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
Rhea-AI Summary
Invivyd, Inc. announces interim exploratory COVID-19 clinical event data for VYD222, an investigational monoclonal antibody for pre-exposure prophylaxis. The data from the Phase 3 CANOPY trial show a potential signal of clinical protection from symptomatic COVID-19. The company plans to further analyze the relationship between serum virus neutralizing antibody titers and clinical efficacy in future trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.1%
Tags
clinical trial
-
News
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
Rhea-AI Summary
Invivyd, Inc. (IVVD) receives emergency use authorization for PEMGARDA, a monoclonal antibody for COVID-19 prevention in immunocompromised individuals. The company anticipates product availability soon, with a strong financial position and ongoing clinical trials supporting its efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.1%
Tags
covid-19
News
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Invivyd, Inc. (IVVD) CEO to present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference to discuss the company's mission to protect against viral infectious diseases and host investor meetings. The live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
conferences
-
News
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
Rhea-AI Summary
Invivyd, Inc. (Nasdaq: IVVD) requests Emergency Use Authorization (EUA) from the FDA for VYD222, a monoclonal antibody candidate for pre-exposure prevention of COVID-19 in immunocompromised individuals. The submission is based on positive results from the CANOPY Phase 3 trial and in vitro neutralization activity against SARS-CoV-2 variants, including JN.1. If authorized, VYD222 could provide a new preventive option for vulnerable individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
acquisition covid-19
-
News
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Rhea-AI Summary
Invivyd, Inc. (IVVD) announced positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial of VYD222, a monoclonal antibody candidate for the prevention of symptomatic COVID-19. VYD222 demonstrated high serum virus neutralizing antibody titer levels in immunocompromised participants, favorable safety and tolerability profile, and continued in-vitro neutralization activity against major SARS-CoV-2 variants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
120.25%
Tags
clinical trial covid-19
News
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Invivyd, Inc. (IVVD) completed enrollment in the CANOPY Phase 3 clinical trial for VYD222, aiming to prevent symptomatic COVID-19. They plan to submit an application for Emergency Use Authorization (EUA) in the U.S. and expect initial primary endpoint data by late 2023 or early Q1 2024. The company also continues to advance INVYMABTM, its proprietary platform approach for generating new antibodies addressing viral threats. With $264.9 million in cash, cash equivalents, and marketable securities, they expect to support operations into Q4 2024, excluding potential commercial product revenue contribution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Stock IVVD logo
Invivyd Inc

Nasdaq:IVVD

IVVD Rankings

#3561 Ranked by Market Cap
#4901 Ranked by Stock Gains
N/A Ranked by Dividends

IVVD Stock Data

351.70M
49.62M
18.21%
63.86%
1.95%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Waltham

About IVVD

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.